Schizoaffective Disorder
Schizoaffective disorder features concurrent psychotic and mood symptoms, with psychotic symptoms also occurring outside mood episodes. It has a prevalence of approximately 0.3%.
Key Facts
Diagnostic criteria require concurrent psychotic AND mood (manic or depressive) symptoms, PLUS a period of psychosis (≥2 weeks) in the absence of prominent mood symptoms Two subtypes: Bipolar type (manic episodes) and depressive type (depressive episodes only) Prevalence approximately 0.3%; more common in women; age of onset similar to schizophrenia Prognosis is intermediate between schizophrenia (worse) and bipolar disorder (better) Treatment combines approaches for both psychosis and mood disorder — antipsychotic + mood stabiliser First-line: Antipsychotic (as for schizophrenia) + mood stabiliser (lithium or valproate depending on subtype) Distinction from schizophrenia: Mood episodes are prominent and occupy a substantial proportion of the total illness duration Distinction from bipolar with psychosis: Psychotic symptoms persist for ≥2 weeks WITHOUT prominent mood symptoms
Overview
Key Facts
Schizoaffective disorder occupies a diagnostic position between schizophrenia and mood disorders. The key distinguishing feature is that psychotic symptoms must be present both during and outside of mood episodes.
Epidemiology
Lifetime prevalence is approximately 0.3%. Slightly more common in women. Age of onset is similar to schizophrenia (late teens to early 30s). Bipolar type may be more common in younger patients.
Aetiology
- Genetic: Shared genetic risk factors with both schizophrenia and bipolar disorder; family studies show increased rates of both conditions in relatives
- Neurochemical: Combined dopaminergic and serotonergic dysregulation
- Neurodevelopmental: Some evidence of intermediate neurodevelopmental abnormalities between schizophrenia and bipolar disorder
- Environmental: Similar risk factors to schizophrenia (substance use, social adversity)
Pathophysiology
- Shares neurobiological features with both schizophrenia and bipolar disorder
- Intermediate brain structural changes — more grey matter loss than bipolar but less than schizophrenia
- Combined dopamine (psychosis) and monoamine (mood) dysregulation
- Some researchers question whether it is a distinct entity or a spectrum between schizophrenia and bipolar disorder
Clinical Presentation
Bipolar Type
- Episodes of mania with concurrent psychotic symptoms
- Depressive episodes may also occur
- Psychotic symptoms persist even when mood normalises
Depressive Type
- Depressive episodes with concurrent psychotic symptoms
- No manic episodes
- Psychotic symptoms persist during euthymic periods
Key Diagnostic Requirement
- Period of at least 2 weeks with delusions/hallucinations in the absence of prominent mood symptoms (distinguishes from bipolar disorder with psychotic features)
Red Flags
- Suicide risk — similar to bipolar disorder (~5-10% lifetime)
- Substance misuse — common comorbidity
- Non-adherence to complex medication regimen
- Treatment-resistant psychotic symptoms — consider clozapine
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| Schizophrenia | Psychosis predominates, mood symptoms secondary and brief | Longitudinal assessment |
| Bipolar disorder with psychotic features | Psychosis only during mood episodes, not independently | Longitudinal assessment |
| Drug-induced psychosis | Temporal relationship to substances | Urine drug screen |
| Major depression with psychotic features | Psychosis only during depressive episodes | Longitudinal assessment |
| Delusional disorder | Non-bizarre delusions, no mood episodes, good functioning | Clinical assessment |
| Organic psychosis | Medical cause, atypical features | MRI, bloods, EEG |
Diagnosis / Investigation
Bedside
- MSE: Comprehensive mental state examination
- Mood charting: Longitudinal documentation of mood episodes and psychotic symptoms
- Risk assessment: Suicide, self-harm, risk to others
- Collateral history: Timeline of mood vs psychotic symptoms
Bloods
- FBC, U&Es, LFTs, TFTs: Baseline and medication monitoring
- Fasting glucose, lipids, HbA1c: Metabolic monitoring
- Lithium level: If on lithium (target 0.6-0.8 mmol/L)
- Urine drug screen: Exclude substance-induced presentation
Special Tests
- ECG: QTc baseline for antipsychotics
- MRI brain: First presentation to exclude organic cause
- Prolactin: If symptoms of hyperprolactinaemia
Management
Non-pharmacological
- Psychoeducation: Understanding the dual nature of the illness
- CBT for psychosis: As per schizophrenia guidelines
- Family intervention: Reduces relapse
- Social support: Supported accommodation, employment support
- Relapse prevention planning: Identify early warning signs for both mood and psychotic episodes
Pharmacological
Bipolar type:
- Antipsychotic (risperidone, olanzapine, quetiapine) + mood stabiliser (lithium or valproate)
- Lithium: 400-1200mg daily, target 0.6-0.8 mmol/L
Depressive type:
- Antipsychotic + antidepressant (SSRI) — caution with antidepressant monotherapy (may worsen psychosis)
- Lamotrigine may be useful for depressive symptoms
Treatment-resistant:
- Clozapine — as per schizophrenia guidelines
- ECT — may be effective for both mood and psychotic components
Referral Criteria
- All patients — secondary care psychiatry for diagnosis confirmation and treatment initiation
- Treatment-resistant — specialist services, clozapine consideration
- Acute relapse with risk — crisis team or inpatient admission
Prognosis
- Intermediate prognosis: Better than schizophrenia, worse than bipolar disorder
- Bipolar type generally has a better outcome than depressive type
- Suicide risk: Approximately 5-10% lifetime
- Functional outcome: Better than schizophrenia; many achieve reasonable social and occupational functioning with treatment
- Relapse: High if medication discontinued — long-term treatment recommended
- Mortality: Reduced life expectancy due to cardiovascular disease, metabolic syndrome, and suicide
Other Relevant Information
Distinguishing Key Diagnoses
| Feature | Schizophrenia | Schizoaffective | Bipolar with Psychosis |
|---|---|---|---|
| Psychosis without mood episodes | Yes (majority of illness) | Yes (≥2 weeks) | No (only during mood episodes) |
| Mood episodes | Brief/absent | Prominent, substantial duration | Core feature |
| Between-episode functioning | Often impaired | Intermediate | Often preserved |
| Prognosis | Worst | Intermediate | Best |
Treatment Summary
| Subtype | Antipsychotic | Mood Treatment |
|---|---|---|
| Bipolar type | Olanzapine, risperidone, quetiapine | Lithium or valproate |
| Depressive type | Olanzapine, risperidone, quetiapine | SSRI or lamotrigine |
| Treatment-resistant | Clozapine | Lithium augmentation, ECT |